3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Carboplatin
11
pembrolizumab
10
Gemcitabine
8
Cisplatin
8
Rituximab
7
osimertinib
5
durvalumab
5
Specimen Handling
5
Pemetrexed
5
Nivolumab
5
Dexamethasone
5
belzutifan
4
atezolizumab
4
amivantamab
4
Prednisone
4
Paclitaxel
4
Cyclophosphamide
4
Bortezomib
4
trastuzumab deruxtecan
3
olaparib
3
lazertinib
3
entrectinib
3
enfortumab vedotin
3
daratumumab
3
alectinib
3
acalabrutinib
3
X-Rays
3
Vinorelbine
3
Oxaliplatin
3
Midazolam
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
revumenib
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA